In the last decade, human genome-wide association study (GWAS) and genome sequencing of large patient samples revealed that MEF2C is a candidate risk gene for various neuropsychiatric disorders, such as AD [67], ASD [83], schizophrenia [47], bipolar disorder [50], major depression [28], attention deficit and hyperactivity disorder [62], epilepsy [80] or Parkinson’s disease [59]. The gene discussed is MEF2C; the disease is schizophrenia.